{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T01:46:39Z","timestamp":1768527999704,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 72404205"],"award-info":[{"award-number":["No. 72404205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 72174142"],"award-info":[{"award-number":["No. 72174142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Tianjin, China","award":["No. 23JCQNJC01650"],"award-info":[{"award-number":["No. 23JCQNJC01650"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s41669-025-00615-w","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T08:42:10Z","timestamp":1762591330000},"page":"167-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health Utility Decrement of Injection Treatment-Related Attributes Using Time Trade-Off Among Type 2 Diabetes Patients: A Vignette-Based Study"],"prefix":"10.1007","volume":"10","author":[{"given":"Xinran","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shitong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6012-2785","authenticated-orcid":false,"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"615_CR1","unstructured":"Magliano DJ, Boyko EJ & Committee IDFDaTES. IDF Diabetes Atlas. Idf diabetes atlas. International Diabetes Federation\u00a9 International Diabetes Federation, 2021;2021."},{"key":"615_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m997","volume":"369","author":"Y Li","year":"2020","unstructured":"Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997. https:\/\/doi.org\/10.1136\/bmj.m997.","journal-title":"BMJ"},{"key":"615_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9121672","author":"CC Chen","year":"2021","unstructured":"Chen CC, Chen JH, Chen CL, Lai TJ, Ko Y. Health utilities in patients with type 2 diabetes in Taiwan. Healthcare. 2021. https:\/\/doi.org\/10.3390\/healthcare9121672.","journal-title":"Healthcare"},{"issue":"4","key":"615_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/14737167.2022.2020106","volume":"22","author":"C Ding","year":"2022","unstructured":"Ding C, Bao Y, Bai B, Liu X, Shi B, Tian L. An update on the economic burden of type 2 diabetes mellitus in China. Expert Rev Pharmacoecon Outcomes Res. 2022;22(4):617\u201325. https:\/\/doi.org\/10.1080\/14737167.2022.2020106.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"Supplement_1","key":"615_CR5","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"Committee, A. D. a. P. P.","year":"2023","unstructured":"Committee, A. D. a. P. P. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024. Diabetes Care. 2023;47(Supplement_1):S158\u201378. https:\/\/doi.org\/10.2337\/dc24-S009.","journal-title":"Diabetes Care"},{"issue":"9","key":"615_CR6","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1007\/s13300-021-01097-9","volume":"12","author":"KS Boye","year":"2021","unstructured":"Boye KS, Jordan JB, Malik RE, Currie BM, Matza LS. Patient perceptions of and preferences between characteristics of injectable diabetes treatments. Diabetes Ther. 2021;12(9):2387\u2013403. https:\/\/doi.org\/10.1007\/s13300-021-01097-9.","journal-title":"Diabetes Ther"},{"issue":"8","key":"615_CR7","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.clinthera.2019.05.003","volume":"41","author":"C Wang","year":"2019","unstructured":"Wang C, Gao Y, Zhu L, Huang M, Wu Y, Xuan J. Treatment patterns in patients with newly diagnosed type 2 diabetes in China: a retrospective, longitudinal database study. Clin Ther. 2019;41(8):1440\u201352. https:\/\/doi.org\/10.1016\/j.clinthera.2019.05.003.","journal-title":"Clin Ther"},{"issue":"3","key":"615_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00592-018-1236-6","volume":"56","author":"G Marchesini","year":"2019","unstructured":"Marchesini G, Pasqualetti P, Anichini R, Caputo S, Memoli G, Ponzani P, et al. Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis. Acta Diabetol. 2019;56(3):289\u201399. https:\/\/doi.org\/10.1007\/s00592-018-1236-6.","journal-title":"Acta Diabetol"},{"issue":"2","key":"615_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jval.2014.12.004","volume":"18","author":"Y Zhong","year":"2015","unstructured":"Zhong Y, Lin PJ, Cohen JT, Winn AN, Neumann PJ. Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence. Value Health. 2015;18(2):308\u201314. https:\/\/doi.org\/10.1016\/j.jval.2014.12.004.","journal-title":"Value Health"},{"issue":"7","key":"615_CR10","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.jval.2021.12.016","volume":"25","author":"H Saunders","year":"2022","unstructured":"Saunders H, Pham B, Loong D, Mishra S, Ashoor HM, Antony J, et al. The cost-effectiveness of intermediate-acting, long-acting, ultralong-acting, and biosimilar insulins for type 1 diabetes mellitus: a systematic review. Value Health. 2022;25(7):1235\u201352. https:\/\/doi.org\/10.1016\/j.jval.2021.12.016.","journal-title":"Value Health"},{"key":"615_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780198725923.001.0001","volume-title":"Measuring and valuing health benefits for economic evaluation","author":"J Brazier","year":"2016","unstructured":"Brazier J, Ratcliffe J, Salomon J, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. OUP Catalogue; 2016."},{"key":"615_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-025-03945-8","author":"S Xie","year":"2025","unstructured":"Xie S, Liu X, Li M, Wu J. Disutility of treatment-related attributes for type 2 diabetes mellitus: a systematic review. Qual Life Res. 2025. https:\/\/doi.org\/10.1007\/s11136-025-03945-8.","journal-title":"Qual Life Res"},{"issue":"7","key":"615_CR13","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1185\/03007995.2014.899207","volume":"30","author":"S Lane","year":"2014","unstructured":"Lane S, Levy AR, Mukherjee J, Sambrook J, Tildesley H. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin. 2014;30(7):1267\u201373. https:\/\/doi.org\/10.1185\/03007995.2014.899207.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"615_CR14","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s11136-007-9226-0","volume":"16","author":"LS Matza","year":"2007","unstructured":"Matza LS, Boye KS, Yurgin N, Brewster-Jordan J, Mannix S, Shorr JM, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res. 2007;16(7):1251\u201365. https:\/\/doi.org\/10.1007\/s11136-007-9226-0.","journal-title":"Qual Life Res"},{"issue":"9","key":"615_CR15","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1185\/030079907x219454","volume":"23","author":"LS Matza","year":"2007","unstructured":"Matza LS, Yurgin N, Boye KS, Malley K, Shorr JM. Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. Curr Med Res Opin. 2007;23(9):2051\u201362. https:\/\/doi.org\/10.1185\/030079907x219454.","journal-title":"Curr Med Res Opin"},{"key":"615_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12955-016-0411-0","volume":"14","author":"M Ridderstr\u00e5le","year":"2016","unstructured":"Ridderstr\u00e5le M, Evans LM, Jensen HH, B\u00f8gelund M, Jensen MM, Ericsson \u00c5, et al. Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study. Health Qual Life Outcomes. 2016;14:13. https:\/\/doi.org\/10.1186\/s12955-016-0411-0.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"615_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10198-010-0224-8","volume":"12","author":"KS Boye","year":"2011","unstructured":"Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12(3):219\u201330. https:\/\/doi.org\/10.1007\/s10198-010-0224-8.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"615_CR18","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1186\/s12913-017-2648-7","volume":"17","author":"LS Matza","year":"2017","unstructured":"Matza LS, Boye KS, Stewart KD, Davies EW, Paczkowski R. Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Serv Res. 2017;17(1):774. https:\/\/doi.org\/10.1186\/s12913-017-2648-7.","journal-title":"BMC Health Serv Res"},{"key":"615_CR19","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2147\/ppa.S159620","volume":"12","author":"LS Matza","year":"2018","unstructured":"Matza LS, Boye KS, Jordan JB, Norrbacka K, Gentilella R, Tiebout AR, et al. Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. Patient Prefer Adherence. 2018;12:971\u20139. https:\/\/doi.org\/10.2147\/ppa.S159620.","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"615_CR20","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s11136-019-02117-9","volume":"28","author":"F Hall","year":"2019","unstructured":"Hall F, De Freitas HM, Kerr C, Ito T, Nafees B, Lloyd AJ, et al. Estimating utilities\/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events. Qual Life Res. 2019;28(5):1191\u20139. https:\/\/doi.org\/10.1007\/s11136-019-02117-9.","journal-title":"Qual Life Res"},{"issue":"2","key":"615_CR21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jval.2020.09.017","volume":"24","author":"M Laxy","year":"2021","unstructured":"Laxy M, Becker J, K\u00e4hm K, Holle R, Peters A, Thorand B, et al. Utility decrements associated with diabetes and related complications: estimates from a population-based study in Germany. Value Health. 2021;24(2):274\u201380. https:\/\/doi.org\/10.1016\/j.jval.2020.09.017.","journal-title":"Value Health"},{"key":"615_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.vhri.2015.11.006","volume":"9","author":"N Rajan","year":"2016","unstructured":"Rajan N, Boye KS, Gibbs M, Lee YJ, Davey P, Ball M, et al. Utilities for type 2 diabetes treatment-related attributes in a South Korean and Taiwanese population. Value Health Reg Issues. 2016;9:67\u201371. https:\/\/doi.org\/10.1016\/j.vhri.2015.11.006.","journal-title":"Value Health Reg Issues"},{"issue":"2","key":"615_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10198-022-01470-w","volume":"24","author":"P Mcewan","year":"2023","unstructured":"Mcewan P, Baker-Knight J, \u00c1sbj\u00f6rnsd\u00f3ttir B, Yi Y, Fox A, Wyn R. Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China. Eur J Health Econ. 2023;24(2):187\u201396. https:\/\/doi.org\/10.1007\/s10198-022-01470-w.","journal-title":"Eur J Health Econ"},{"issue":"8","key":"615_CR24","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10198-020-01195-8","volume":"21","author":"M Kennedy-Martin","year":"2020","unstructured":"Kennedy-Martin M, Slaap B, Herdman M, Van Reenen M, Kennedy-Martin T, Greiner W, et al. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ. 2020;21(8):1245\u201357. https:\/\/doi.org\/10.1007\/s10198-020-01195-8.","journal-title":"Eur J Health Econ"},{"issue":"2","key":"615_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jval.2019.08.009","volume":"23","author":"E Goodwin","year":"2020","unstructured":"Goodwin E, Green C, Hawton A. What difference does it make? A comparison of health state preferences elicited from the general population and from people with multiple sclerosis. Value Health. 2020;23(2):242\u201350. https:\/\/doi.org\/10.1016\/j.jval.2019.08.009.","journal-title":"Value Health"},{"issue":"6","key":"615_CR26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2020.12.017","volume":"24","author":"LS Matza","year":"2021","unstructured":"Matza LS, Stewart KD, Lloyd AJ, Rowen D, Brazier JE. Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health. 2021;24(6):812\u201321. https:\/\/doi.org\/10.1016\/j.jval.2020.12.017.","journal-title":"Value Health"},{"issue":"Suppl 1","key":"615_CR27","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","volume":"13","author":"S Cuschieri","year":"2019","unstructured":"Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl 1):S31-s34. https:\/\/doi.org\/10.4103\/sja.SJA_543_18.","journal-title":"Saudi J Anaesth"},{"issue":"8","key":"615_CR28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40273-015-0292-9","volume":"33","author":"F Xie","year":"2015","unstructured":"Xie F, Pickard AS, Krabbe PF, Revicki D, Viney R, Devlin N, et al. A checklist for reporting valuation studies of multi-attribute utility-based instruments (CREATE). Pharmacoeconomics. 2015;33(8):867\u201377. https:\/\/doi.org\/10.1007\/s40273-015-0292-9.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"615_CR29","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.jval.2020.06.010","volume":"23","author":"S Xie","year":"2020","unstructured":"Xie S, Wu J, He X, Chen G, Brazier JE. Do discrete choice experiments approaches perform better than time trade-off in eliciting health state utilities? Evidence from SF-6Dv2 in China. Value Health. 2020;23(10):1391\u20139. https:\/\/doi.org\/10.1016\/j.jval.2020.06.010.","journal-title":"Value Health"},{"issue":"1","key":"615_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jval.2023.08.015","volume":"27","author":"Z Yang","year":"2024","unstructured":"Yang Z, Devlin NJ, Rand K, Luo N. Testing 2 alternative time trade-off methods for valuation of children\u2019s health states. Value Health. 2024;27(1):43\u201350. https:\/\/doi.org\/10.1016\/j.jval.2023.08.015.","journal-title":"Value Health"},{"issue":"4","key":"615_CR31","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","volume":"20","author":"N Luo","year":"2017","unstructured":"Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K. Estimating an EQ-5D-5L value set for China. Value Health. 2017;20(4):662\u20139. https:\/\/doi.org\/10.1016\/j.jval.2016.11.016.","journal-title":"Value Health"},{"issue":"5","key":"615_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40273-020-00997-1","volume":"39","author":"J Wu","year":"2021","unstructured":"Wu J, Xie S, He X, Chen G, Bai G, Feng D, et al. Valuation of SF-6Dv2 health states in China using time trade-off and discrete-choice experiment with a duration dimension. Pharmacoeconomics. 2021;39(5):521\u201335. https:\/\/doi.org\/10.1007\/s40273-020-00997-1.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"615_CR33","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1007\/s12325-022-02181-7","volume":"39","author":"JH Shubrook","year":"2022","unstructured":"Shubrook JH, Radin M, Ali SN, Chubb B, Dipietrantonio K, Collings H, et al. Preference for type 2 diabetes therapies in the United States: a discrete choice experiment. Adv Ther. 2022;39(9):4114\u201330. https:\/\/doi.org\/10.1007\/s12325-022-02181-7.","journal-title":"Adv Ther"},{"issue":"1","key":"615_CR34","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s12325-020-01561-1","volume":"38","author":"A Igarashi","year":"2021","unstructured":"Igarashi A, Bekker Hansen B, Langer J, Tavella F, Collings H, Davies N, et al. Preference for oral and injectable GLP-1 RA therapy profiles in Japanese patients with type 2 diabetes: a discrete choice experiment. Adv Ther. 2021;38(1):721\u201338. https:\/\/doi.org\/10.1007\/s12325-020-01561-1.","journal-title":"Adv Ther"},{"issue":"8","key":"615_CR35","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40273-013-0066-1","volume":"31","author":"VK Brennan","year":"2013","unstructured":"Brennan VK, Dixon S. Incorporating process utility into quality adjusted life years: a systematic review of empirical studies. Pharmacoeconomics. 2013;31(8):677\u201391. https:\/\/doi.org\/10.1007\/s40273-013-0066-1.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"615_CR36","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jval.2020.12.019","volume":"24","author":"CH Mok","year":"2021","unstructured":"Mok CH, Kwok HHY, Ng CS, Leung GM, Quan J. Health state utility values for type 2 diabetes and related complications in East and Southeast Asia: a systematic review and meta-analysis. Value Health. 2021;24(7):1059\u201367. https:\/\/doi.org\/10.1016\/j.jval.2020.12.019.","journal-title":"Value Health"},{"issue":"2","key":"615_CR37","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jval.2015.11.012","volume":"19","author":"KS Gries","year":"2016","unstructured":"Gries KS, Regier DA, Ramsey SD, Patrick DL. Preferences for prostate cancer outcomes: a comparison of the patient perspective, the general population perspective, and a population at risk for prostate cancer. Value Health. 2016;19(2):218\u201325. https:\/\/doi.org\/10.1016\/j.jval.2015.11.012.","journal-title":"Value Health"},{"issue":"9","key":"615_CR38","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.jval.2021.02.012","volume":"24","author":"K Ludwig","year":"2021","unstructured":"Ludwig K, Ramos-Go\u00f1i JM, Oppe M, Kreimeier S, Greiner W. To what extent do patient preferences differ from general population preferences? Value Health. 2021;24(9):1343\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.02.012.","journal-title":"Value Health"},{"issue":"2","key":"615_CR39","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0033","volume":"13","author":"D Aggio","year":"2024","unstructured":"Aggio D, Gallop K, Wittrup-Jensen V, Farsani SF, Lloyd AJ. Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment. J Comp Eff Res. 2024;13(2):e230033. https:\/\/doi.org\/10.57264\/cer-2023-0033.","journal-title":"J Comp Eff Res"},{"issue":"7","key":"615_CR40","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40273-019-00775-8","volume":"37","author":"H Shao","year":"2019","unstructured":"Shao H, Yang S, Fonseca V, Stoecker C, Shi L. Estimating quality of life decrements due to diabetes complications in the United States: the health utility index (HUI) diabetes complication equation. Pharmacoeconomics. 2019;37(7):921\u20139. https:\/\/doi.org\/10.1007\/s40273-019-00775-8.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"615_CR41","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hec.2930","volume":"23","author":"M Alva","year":"2014","unstructured":"Alva M, Gray A, Mihaylova B, Clarke P. The effect of diabetes complications on health-related quality of life: the importance of longitudinal data to address patient heterogeneity. Health Econ. 2014;23(4):487\u2013500. https:\/\/doi.org\/10.1002\/hec.2930.","journal-title":"Health Econ"},{"issue":"6","key":"615_CR42","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jval.2016.06.001","volume":"19","author":"SE Wolowacz","year":"2016","unstructured":"Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, et al. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health. 2016;19(6):704\u201319. https:\/\/doi.org\/10.1016\/j.jval.2016.06.001.","journal-title":"Value Health"},{"key":"615_CR43","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2147\/ppa.S187907","volume":"13","author":"VT Thieu","year":"2019","unstructured":"Thieu VT, Robinson S, Kennedy-Martin T, Boye KS, Garcia-Perez LE. Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes. Patient Prefer Adherence. 2019;13:561\u201376. https:\/\/doi.org\/10.2147\/ppa.S187907.","journal-title":"Patient Prefer Adherence"},{"key":"615_CR44","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2147\/ppa.S101821","volume":"10","author":"KD Stewart","year":"2016","unstructured":"Stewart KD, Johnston JA, Matza LS, Curtis SE, Havel HA, Sweetana SA, et al. Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence. 2016;10:1385\u201399. https:\/\/doi.org\/10.2147\/ppa.S101821.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"615_CR45","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1186\/s12913-018-3484-0","volume":"18","author":"S Fifer","year":"2018","unstructured":"Fifer S, Rose J, Hamrosi KK, Swain D. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment. BMC Health Serv Res. 2018;18(1):675. https:\/\/doi.org\/10.1186\/s12913-018-3484-0.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"615_CR46","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/hsc.12052","volume":"21","author":"A Sav","year":"2013","unstructured":"Sav A, Kendall E, Mcmillan SS, Kelly F, Whitty JA, King MA, et al. \u201cYou say treatment, I say hard work\u201d: treatment burden among people with chronic illness and their carers in Australia. Health Soc Care Community. 2013;21(6):665\u201374. https:\/\/doi.org\/10.1111\/hsc.12052.","journal-title":"Health Soc Care Community"},{"key":"615_CR47","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/1471-2296-14-164","volume":"14","author":"H Abu Hassan","year":"2013","unstructured":"Abu Hassan H, Tohid H, Mohd Amin R, Long Bidin MB, Muthupalaniappen L, Omar K. Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: a qualitative exploration. BMC Fam Pract. 2013;14:164. https:\/\/doi.org\/10.1186\/1471-2296-14-164.","journal-title":"BMC Fam Pract"},{"issue":"2","key":"615_CR48","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jval.2022.08.011","volume":"26","author":"M Jakubczyk","year":"2023","unstructured":"Jakubczyk M, Lipman SA, Roudijk B, Norman R, Pullenayegum E, Yang Y, et al. Modifying the composite time trade-off method to improve its discriminatory power. Value Health. 2023;26(2):280\u201391. https:\/\/doi.org\/10.1016\/j.jval.2022.08.011.","journal-title":"Value Health"},{"issue":"4","key":"615_CR49","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40258-022-00715-2","volume":"20","author":"S Xie","year":"2022","unstructured":"Xie S, Wu J, Xie F. Population norms for SF-6Dv2 and EQ-5D-5L in China. Appl Health Econ Health Policy. 2022;20(4):573\u201385. https:\/\/doi.org\/10.1007\/s40258-022-00715-2.","journal-title":"Appl Health Econ Health Policy"},{"issue":"11","key":"615_CR50","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1007\/s11136-020-02551-0","volume":"29","author":"CW Pan","year":"2020","unstructured":"Pan CW, Zhang RY, Luo N, He JY, Liu RJ, Ying XH, et al. How the EQ-5D utilities are derived matters in Chinese diabetes patients: a comparison based on different EQ-5D scoring functions for China. Qual Life Res. 2020;29(11):3087\u201394. https:\/\/doi.org\/10.1007\/s11136-020-02551-0.","journal-title":"Qual Life Res"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00615-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00615-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00615-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:04:14Z","timestamp":1768471454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00615-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00615-w","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"7 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Concept and design: SX and JW. Acquisition of data: SX and XL. Analysis and interpretation of data: XL, CL, and SX. Drafting of the manuscript: XL, CL, and SX. Statistical analysis: XL, CL, and SX. Obtaining funding: SX and JW. Supervision: JW. All authors commented on previous versions of the manuscript and approved the final manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"SX reported receiving grants from the National Natural Science Foundation of China, and the Natural Science Foundation of Tianjin, China during the conduct of the study. JW reported receiving grants from the National Natural Science Foundation of China during the conduct of the study. Jing Wu is an Editorial Board member of PharmacoEconomics - Open. Jing Wu was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. No other conflicts of interest were reported by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Informed consent was obtained from all individual participants included in the study. Participants were informed about their freedom of refusal. Anonymity and confidentiality were maintained throughout the research process.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The datasets used and analyzed can be obtained from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Informed consent was obtained prior to data collection. This study was approved by the Academic Ethics Committee at Tianjin University (No. TJUE-2023-206).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The code can be obtained from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Informed consent for publication was obtained from all participants prior to their involvement in the study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}